Skip to main content
“There are a terrible lot of lies going about the world, and the worst of it is that
half of them are true.” – Win

Dr. John Cush RheumNow

1 year 2 months ago
“There are a terrible lot of lies going about the world, and the worst of it is that half of them are true.” – Winston Churchill
HCQ Preserves Renal Function in Lupus Nephritis

Lupus nephritis (LN) patients on long-term therapy with hydroxychloroq

Dr. John Cush RheumNow

1 year 2 months ago
HCQ Preserves Renal Function in Lupus Nephritis Lupus nephritis (LN) patients on long-term therapy with hydroxychloroquine (HCQ) showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated. https://t.co/YpJGpAysUQ
Top 20 Best Rheumatology Hospitals - 2025

Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year

Dr. John Cush RheumNow

1 year 2 months ago
Top 20 Best Rheumatology Hospitals - 2025 Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year in a row Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. https://t.co/gBA49giwX7 https://t.co/sObhLxgrBf
MTX or TNFi use in elderly #RA pts w/in a year of Dx of melanoma was not associated with increased mortality. This inclu

Dr. John Cush RheumNow

1 year 2 months ago
MTX or TNFi use in elderly #RA pts w/in a year of Dx of melanoma was not associated with increased mortality. This included melanoma in situ (48%), localized (47%) and regional (5%) melanoma. Steroid use however was assoc w/ reduced survival. https://t.co/QOXfEf51S1 https://t.co/GZ5dedEMfM
Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.
A New RA Approval (8.1.2025)
Rituximab is not Superior in EGPA

A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from

Dr. John Cush RheumNow

1 year 2 months ago
Rituximab is not Superior in EGPA A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination https://t.co/h4B20Ngamj
FDA is evaluating the safety of Vyvgart Hytrulo, ((efgartigimod) used to treat AChR Ab positive generalized myasthenia

Dr. John Cush RheumNow

1 year 2 months ago
FDA is evaluating the safety of Vyvgart Hytrulo, ((efgartigimod) used to treat AChR Ab positive generalized myasthenia gravis (gMG). But in clinical trials there are reports of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)” https://t.co/KN7ZZ2LWPW
PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72

Dr. John Cush RheumNow

1 year 2 months ago
PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/wbiVhjCimk
Pregnant Women on TNFi more likely to use throughout gestation, w/ less steroids. 3711 preg on TNFi in 49,925 F (w/ RA,

Dr. John Cush RheumNow

1 year 2 months ago
Pregnant Women on TNFi more likely to use throughout gestation, w/ less steroids. 3711 preg on TNFi in 49,925 F (w/ RA, AS, PsA, PsO, IBD) -- 64% had 3 trimester TNFi use. 89% exposed preconception & 68% cont postpartum. TNFi use incr from 55% to 73% i(20111-21) https://t.co/DVvbwx6MoW
TriNetX study of E-health record study of ~53k transcatheter aortic valve intervention (TAVI) pts. 705 were on preoperat

Dr. John Cush RheumNow

1 year 2 months ago
TriNetX study of E-health record study of ~53k transcatheter aortic valve intervention (TAVI) pts. 705 were on preoperative colchicine - these had signif reduction of post-TAVI heart block and AV/LBBB (RR 0.867 [95% CI, 0.756–0.994]) @ 1 month, but not at 6 months https://t.co/wuwlzE22q2
Rheumatology Salaries Remain Low

The annual Medscape Physician Compensation report was published and shows only modest

Dr. John Cush RheumNow

1 year 2 months ago
Rheumatology Salaries Remain Low The annual Medscape Physician Compensation report was published and shows only modest salary gains for most specialists. https://t.co/NcmwrMxpKr https://t.co/mxFbqtUQv2
CARRA registry study of 2,956 JIA pts (activity: 71% inactive/minimal, 25% persistent moderate/high, 2% “improving”

Dr. John Cush RheumNow

1 year 2 months ago
CARRA registry study of 2,956 JIA pts (activity: 71% inactive/minimal, 25% persistent moderate/high, 2% “improving”, 2% “flaring”). In 12 mos, Only 10% had DMARD escalation & only 15% escalation despite 2 consecutive visits w/ persistent moderate/high disease activity. This is https://t.co/Gviwgfcdrk
SetPoint Medical announced that the FDA has approved the company’s SetPoint System, a first-in-class neuroimmune modulation innovation for treatment of moderate-to-severe rheumatoid arthritis (RA) for those who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, such as biological and targeted synthetic DMARDs.
Options for Refractory axSpA or PsA
  • MedPage Today
Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such cases, a Danish registry study indicated.
×